Back-to-school season is an exciting time of year, but it’s also the start of something no one likes: flu season. And in case you didn't already know: The top science-backed way to lower your risk of ...
In Cuba, the routine immunization (RI) schedule for polio consists of two doses of fIPV administered at 4 and 8 months of age administered intradermally with N/S. However, ID administration with N/S ...
More children died from the flu this past season than any year outside of the swine flu pandemic in 2009. Most of them were unvaccinated. That's why some doctors are hoping that the first nasal flu ...
ObvioHealth, a global leader in digital clinical trial solutions, announced that it has signed a three-year agreement with Vaxxas, a clinical-stage biotechnology company pioneering a needle-free ...
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration ...
ASTMH presentations to focus on why an increasing number of drug developers are exploring benefits that Tropis ID brings to their product development ...
The Needle-Free Injection System Market represents a groundbreaking advancement in medical technology, offering an innovative ...
Researchers led by a team at INSERM and King’s College London have shown how stretching the skin stimulates immune cells and increases the skin’s ability to absorb large molecules, including those ...
Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.
About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback